Your browser doesn't support javascript.
loading
The Association Between Frailty and Chronic Lung Allograft Dysfunction After Lung Transplantation.
Singer, Jonthan P; Gao, Ying; Huang, Chiung-Yu; Kordahl, Rose C; Sriram, Anya; Hays, Steven R; Kukreja, Jasleen; Venado, Aida; Calabrese, Daniel R; Greenland, John R.
Afiliação
  • Singer JP; Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Gao Y; Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Huang CY; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.
  • Kordahl RC; Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Sriram A; Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Hays SR; Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Kukreja J; San Francisco Veterans Affairs Health Care System, San Francisco, CA.
  • Venado A; Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Calabrese DR; Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Greenland JR; San Francisco Veterans Affairs Health Care System, San Francisco, CA.
Transplantation ; 107(10): 2255-2261, 2023 10 01.
Article em En | MEDLINE | ID: mdl-37287095
ABSTRACT

BACKGROUND:

After lung transplantation, both frailty and chronic lung allograft dysfunction (CLAD) commonly develop, and when they do, are associated with poorer outcomes. Given their potential shared mechanisms, we sought to explore the temporal relationship between frailty and CLAD onset.

METHODS:

In a single center, we prospectively measured frailty by the short physical performance battery (SPPB) repeatedly after transplant. Because of the nature of the relationship between frailty and CLAD is unknown, we tested the association between frailty, modeled as a time-dependent predictor, and CLAD development as well as CLAD development, modeled as a time-dependent predictor, and frailty development. To do so, we used Cox proportional cause-specific hazards and conditional logistic regression models adjusted for age, sex, race, diagnosis, cytomegalovirus serostatus, posttransplant body mass index, and acute cellular rejection episodes as time-dependent covariates. We tested SPPB frailty as a binary (≤9 points) and continuous predictor (12-point scale); as an outcome, we defined frailty as SPPB ≤9.

RESULTS:

The 231 participants were a mean age of 55.7 y (SD 12.1). After adjusting for covariates, the development of frailty within 3 y after lung transplant was associated with cause-specific CLAD risk (adjusted cause-specific hazard ratio 1.76; 95% confidence interval [CI], 1.05-2.92 when defining frailty as SPPB ≤9 and adjusted cause-specific hazard ratio 1.10, 95% CI, 1.03-1.18 per 1-point worsening in SPPB). CLAD onset did not appear to be a risk factor for subsequent frailty (odds ratio, 4.0; 95% CI, 0.4-197.0).

CONCLUSIONS:

Studying the mechanisms underlying frailty and CLAD could provide new insights into the pathobiology of both and potential targets for intervention.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Pulmão / Fragilidade Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Pulmão / Fragilidade Idioma: En Ano de publicação: 2023 Tipo de documento: Article